Clinical Trials Logo

Afibrinogenemia clinical trials

View clinical trials related to Afibrinogenemia.

Filter by:

NCT ID: NCT02267226 Completed - Clinical trials for Congenital Fibrinogen Deficiency

Efficacy and Safety Study of Octafibrin for On-demand Treatment of Acute Bleeding and to Prevent Bleeding During and After Surgery

Start date: September 2014
Phase: Phase 3
Study type: Interventional

The purpose of the study is to assess the efficacy and safety of Octafibrin for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiency.

NCT ID: NCT02094430 Completed - Clinical trials for Afibrinogenemia, Congenital

Human Fibrinogen Concentrate (FGTW) in Pediatric Patients With Congenital Fibrinogen Deficiency

Start date: January 2014
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of the study is to evaluate clinical pharmacology, efficacy and safety of FGTW in pediatric patients with congenital fibrinogen deficiency.

NCT ID: NCT02065882 Completed - Clinical trials for Congenital Afibrinogenemia

Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency

Start date: March 2013
Phase: Phase 3
Study type: Interventional

The purpose of the study is to investigate pharmacokinetics, efficacy and safety of BT524 in patients with congenital fibrinogen deficiency.

NCT ID: NCT01575756 Completed - Clinical trials for Congenital Fibrinogen Deficiency

Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap

Start date: June 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to investigate pharmacokinetic properties, surrogate efficacy and safety of Octafibrin compared to Haemocomplettan® P/RiaSTAPTM in patients with congenital fibrinogen deficiency

NCT ID: NCT01124981 Completed - Clinical trials for Fibrinogen Deficiency in Complex Cardiac Surgery

Haemocomplettan® P During Elective Complex Cardiac Surgery

Start date: February 2011
Phase: Phase 2/Phase 3
Study type: Interventional

Fibrinogen concentrate is increasingly used in cardiac surgery to reverse coagulopathy. Whether its use reduces blood loss, transfusion and occurrence of clinical adverse events remains unknown.

NCT ID: NCT00916656 Withdrawn - Hypofibrinogenemia Clinical Trials

Fibrinogen Concentrate (Human) - Efficacy and Safety Study

Start date: October 2009
Phase: Phase 3
Study type: Interventional

This is a multinational, multicenter, prospective, open-label historically controlled Phase IIIb non-inferiority clinical trial on the efficacy and safety of Fibrinogen Concentrate (Human). It is estimated that 150-300 patients in the U.S. suffer from afibrinogenemia. Substitution with cryoprecipitate or alternative treatments have limited safety and efficacy. The primary purpose of the study is to demonstrate the hemostatic efficacy of Fibrinogen Concentrate (Human) by adequately controlling acute bleeding (spontaneous or after trauma) in patients with congenital fibrinogen deficiency (afibrinogenemia and hypofibrinogenemia). Cryoprecipitate hemostatic efficacy data from a retrospective physician survey will be used as a historical control.

NCT ID: NCT00496262 Completed - Clinical trials for Fibrinogen Deficiency

Human Fibrinogen - Pharmacokinetics

Start date: July 2007
Phase: Phase 2
Study type: Interventional

This study evaluated the single-dose pharmacokinetics of human fibrinogen concentrate and clot strength (maximum clot firmness [MCF]) in subjects with congenital fibrinogen deficiency. MCF was measured to demonstrate the functional activity of replacement fibrinogen when a fixed dose of human fibrinogen concentrate was administered.